NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
Clinical Trials
29 trialsNCT06194877 2025-04-20
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC
Phase 1 Terminated
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT03311750 2021-06-07
A-REPEAT
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT02448810 2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
Phase 2 Terminated
NCT02015923 2021-03-16
CCRe-IV
Hospital Universitari de Bellvitge
Phase 4 Terminated
NCT03300609 2020-06-11
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
University of Southern California
Phase 3 Terminated
NCT01504477 2020-03-16
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Georgetown University
Phase 1/2 Terminated
NCT01057017 2020-02-17
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Brown University
Phase 2 Terminated
NCT01128387 2019-12-09
Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer
University of Wisconsin, Madison
Phase 1/2 Terminated
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT01009983 2018-07-06
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01627379 2018-03-02
POWER
AIO-Studien-gGmbH
Phase 3 Terminated
NCT01508000 2016-10-12
BOS2
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT02199223 2016-09-22
Regorafenib + Panitumumab for Colorectal Cancers
University of Utah
Phase 1 Terminated
NCT00973193 2016-04-20
PrePaRad
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT01916109 2016-02-12
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01296035 2015-08-25
PanGem
Women and Infants Hospital of Rhode Island
Phase 2 Terminated
NCT01374789 2015-06-03
PURO
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2 Terminated
NCT01038037 2014-12-04
Lung-TRIO
Vejle Hospital
Phase 2 Terminated
NCT01305772 2014-08-29
TOP0901
Duke University
Phase 2 Terminated
NCT01418742 2014-07-14
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 2 Terminated
NCT00101907 2014-03-20
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
Amgen
Phase 1 Terminated
NCT00613730 2014-01-06
APPRISE 1
Amgen
Phase 2 Terminated
NCT01017653 2013-09-04
Panitumumab and Irinotecan for Malignant Gliomas
Duke University
Phase 2 Terminated
NCT00950820 2013-03-04
VOXEL
AIO-Studien-gGmbH
Phase 2 Terminated
NCT00824785 2012-12-11
REAL3
Royal Marsden NHS Foundation Trust
Phase 3 Terminated
NCT01262183 2012-05-11
PANORAMIC
Radboud University Medical Center
Phase 2 Terminated